Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs

The atmosphere of the exchange was enthusiastic and congenial. Hengrui Pharma's Vice General Manager & Global R&D President Lianshan Zhang, along with other executives, visited Medicilon's Pudong Chuansha Park. They were welcomed by Medicilon's CEO Chunlin Chen and key team members. The atmosphere of the exchange was enthusiastic and congenial.  Hengrui Pharma's Vice General Manager & Global R&D President Lianshan Zhang, along with other executives, visited Medicilon's Pudong Chuansha...

The atmosphere of the exchange was enthusiastic and congenial. Hengrui Pharma's Vice General Manager & Global R&D President Lianshan Zhang, along with other executives, visited Medicilon's Pudong Chuansha Park. They were welcomed by Medicilon's CEO Chunlin Chen and key team members.

During the visit, Medicilon's R&D Team introduced their one-stop preclinical services platform for pharmaceutical R&D. They highlighted the Medicilon's capabilities and technical strengths in safety evaluation, pharmacology, and pharmacokinetics, with special attention to PROTAC, ADC, nucleic acids, bispecific antibodies, peptides, vaccines, and CGT. 

Hengrui Pharma's Vice General Manager & Global R&D President Lianshan Zhang stated, "Medicilon possesses robust innovation capabilities and service quality in this field, making it a trusted CRO partner. The collaboration between Hengrui Pharma and Medicilon not only acknowledges past achievements but also represents a deep exploration of future collaboration potential and forward-looking strategic planning." 

Medicilon's Founder & CEO Chunlin Chen stated, "Medicilon and Hengrui Pharma firmly believe that, through close collaboration, the process of drug R&D will be accelerated in the future, contributing to the innovative development of the global pharmaceutical industry."

Website: https://www.medicilon.com/ 

Photo - https://mma.prnewswire.com/media/2472643/Dr_Chunlin_Chen_Dr_Lianshan_Zhang_Strategic_Cooperation_Signing_Ceremony.jpg

View original content:https://www.prnewswire.co.uk/news-releases/medicilon-and-hengrui-pharma-deepen-strategic-collaboration-to-support-innovation-in-adcs-small-nucleic-acids-and-cgt-drugs-302211212.html